A. Lockhart

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

K. Kelly, G. Weiss, A. Heydebreck, 2016 .

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.

S. Leong, T. Pitts, A. Hansen, 2018, Cancer research.

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

E. Chan, D. Camidge, S. Leong, 2012, Cancer Chemotherapy and Pharmacology.

A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors

A. Lockhart, R. Bukowski, M. Rothenberg, 2012, Investigational New Drugs.

Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).

N. Senzer, J. Bendell, A. Lockhart, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.

T. Zander, J. Machiels, J. Schellens, 2019, JCO precision oncology.

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.

A. DeMichele, B. Melichar, P. Zatloukal, 2015, The Lancet. Oncology.

Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors

A. Zhu, L. Appleman, A. Lockhart, 2007, Cancer Chemotherapy and Pharmacology.